Women’s Health & OB/GYN News

The combination of pembrolizumab and chemoradiotherapy significantly improved OS for women with high-risk locally advanced cervical cancer, according to results of a randomized phase 3 trial presented at ESMO Congress.

Exposure to air pollution over a half-decade increased the risk for infertility in men, the results of a nationwide cohort study published in BMJ showed.

CHICAGO — Busy women physicians have much to gain by seeking out small moments of self-care, reflecting on ways to make positive change and sharing their personal stories with other women to build a more connected community.

CHICAGO — Hormone therapy use among menopausal women has fallen to just 1.8% as of 2023, data show, despite evidence and clinical guidance suggesting HT is safe and effective for most women for bothersome menopausal symptoms.

CHICAGO — Female pattern hair loss is a common condition for menopausal women, but options to reverse and regrow hair are available if patients are diagnosed and treated, according to a speaker at the Annual Meeting of The Menopause Society.

CHICAGO — In this Healio video exclusive, Susan D. Reed, MD, MPH, MS, past president of The Menopause Society, highlights a new pilot program created to improve funding for research in menopause health, with up to four awards of $25,000 each.

The FDA issued a warning that use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot flashes, can cause rare but serious liver injury, according to an agency press release.

CHICAGO — The benefits of AI-assisted technology in medicine are rapidly extending to obstetrics and gynecology, with programs in development or already deployed to predict everything from mode of delivery during labor to cervical cancer risk.

CHICAGO — In this Healio video exclusive, Pauline M. Maki, PhD, provides three takeaways from her talk on cognition and hormone therapy during menopause at the Annual Meeting of The Menopause Society.

CHICAGO — Nonhormonal elinzanetant was associated with fewer moderate to severe vasomotor symptoms compared with placebo for up to 1 year, along with similar long-term positive safety data, researchers reported.